This indicates that the improvements with duloxetine were not a result of more frequent voiding by the patients in the study. |
|
Yesterday, Lilly said that it would also significantly increase its efforts to develop duloxetine, another antidepressant. |
|
The data show that response to duloxetine was fastest for the core emotional and painful physical symptoms of depression. |
|
The safety and efficacy of duloxetine are still under investigation and market authorization has not yet been obtained. |
|
In these combined studies, patients on duloxetine also reported improvements on scales used to measure effects on their quality of life. |
|
These data demonstrate that in these patients duloxetine was effective at providing improvements in symptoms of depression as early as one week. |
|
This study demonstrates that in these patients duloxetine was effective at keeping depression at bay. |
|
This study clearly indicates that patients who continued taking duloxetine for six months had a significantly reduced risk of their depression symptoms returning. |
|
The submission package to support the efficacy and safety of duloxetine consisted of data collected from studies that enrolled nearly 3,000 patients with depression. |
|
In addition to the treatment of stress urinary incontinence in women, duloxetine is also currently being developed for the treatment of depression and diabetic neuropathic pain. |
|
These include venlafaxine, escitalopram, duloxetine, mirtazapine, citalopram, fluoxetine, bupropion, sertraline, amitriptyline and trazodone. |
|
This press release contains forward-looking statements about the potential of an investigational compound, duloxetine, for the treatment of depression and reflects Lilly's current beliefs. |
|
As duloxetine is also approved for the treatment of major depressive disorders, drug plans should ensure that reimbursement is confined to patients with diabetic peripheral neuropathic pain. |
|
In the double-blind continuation phase, 278 patients who no longer met criteria for depression were then randomized to either duloxetine 60mg once daily or placebo for an additional 26 weeks. |
|
Examiners found ethyl alcohol, the intoxicating ingredient in alcoholic drinks, and two antidepressants, citalopram and duloxetine, in Ms. Gotbaum's body. |
|
Lilly, based in Indianapolis, aims to use duloxetine to revive its antidepressant franchise, which has been decimated by copycats of its antidepressant Prozac. |
|
Activation of mania or hypomania has occurred in patients treated with duloxetine. |
|
Clinically, our patients electing to continue duloxetine have not reported tachyphylaxis. |
|
After the first month of therapy, the incidence of these adverse events did not differ significantly between duloxetine and placebo-treated patients. |
|
Consistent with improvements in these primary outcomes measures, there were also improvements in several measures of quality of life for duloxetine compared with placebo. |
|
|
Long-term safety data of duloxetine in the management of diabetic peripheral neuropathic pain beyond 12 weeks has not been assessed in controlled trials. |
|
The dose of duloxetine should be limited to a maximum of 60 mg daily. |
|
An in vitro study showed that duloxetine hydrochloride has a molecular binding profile of a dual serotonin and norepinephrine re-uptake inhibitor. |
|
The approval, which was announced on June 16, makes duloxetine the second drug okayed by the agency for this syndrome. |
|
Lilly said its research showed that 80 milligrams of duloxetine a day was more effective than 20 milligrams of Paxil, using a common scale to measure depression. |
|
Antidepressant drugs including SSRIs, trazodone, nefazodone, buspirone, clomipramine, venlafaxine, and duloxetine may be associated with the serotonin syndrome. |
|
Duloxetine delayed-release capsules are AB rated to Cymbalta, a drug which is marketed by Eli Lilly, to treat major depressive disorder. |
|
Duloxetine works centrally on the ascending and descending pain pathways by modulating both noradrenalin and serotonin. |
|
The 15th edition includes coverage of Duloxetine, Eszopiclone, and Acamprosate. |
|